Development of Oral Fast-Disintegrating Levothyroxine Films for Management of Hypothyroidism in Pediatrics by Zhang, He et al.
Zhang et al 
Trop J Pharm Res, October 2015; 14(10): 1755  
 
Tropical Journal of Pharmaceutical Research October 2015; 14(10): 1755-1762 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v14i10.4 
Original Research Article 
 
 
Development of Oral Fast-Disintegrating Levothyroxine 
Films for Management of Hypothyroidism in Pediatrics 
 
He Zhang*, Mei-Gui Han, Yun Wang, Jie Zhang, Zi-Ming Han and Shu-Jun Li 
Department of Pediatrics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China 
 
*For correspondence: Email: zhanghe094@gmail.com; Tel/Fax: 0086-373-4402514 
 
Received: 9 April 2015        Revised accepted: 31 August 2015 
 
Abstract 
Purpose: To develop fast disintegrating films of levothyroxine (LVX) using hydrophilic hydroxypropyl 
methylcellulose (HPMC), croscarmellose sodium (CCS) as superdisintegrant, and propylene glycol (PG) 
as a plasticizer.  
Methods: Fast-disintegrating films were formulated by solvent casting evaporation method using 3-
factor, 2-level full factorial design. The films were evaluated for disintegration time, in vitro drug release, 
physical appearance, thickness, weight variation, folding endurance, drug content uniformity, The effect 
of concentration of dependent variables (HPMC, CCS and PG) on disintegration time and in vitro drug 
release was studied. 
Results: Suitable fast-disintegrating films were obtained using HPMC, CCS and PG. The minimum 
disintegration time (DT) was 15 s  and maximum  drug release (DR) in 1 h was 97.56 %. All 
independent variables selected for the study were statistically significant (p < 0.5). Increase in the 
concentrations of independent variables increased DR and DT.  
Conclusion: The findings of this study indicate that the developed fast-disintegrating film is suitable for 
levothyroxine in the management of hypothyroidism in pediatrics. 
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Hypothyroidism, often referred to as underactive 
thyroid, low thyroid and sometimes, 
hypothyreosis, is a common endocrine disorder 
in which the thyroid gland does not produce 
enough thyroid hormone [1,2]. It is associated 
with tiredness, poor ability to tolerate cold, and 
weight gain. In children, hypothyroidism leads to 
delay in growth and intellectual development, 
known as cretinism in severe cases [3]. The age 
of symptom onset is unpredictable in a child who 
has thyroid dysgenesis with a hypoplastic and or 
ectopic thyroid gland because initial increases in 
Thyroid stimulating harmone (TSH) may be able 
to initially overcome the relative insufficiency of 
the thyroid gland. Newborn children with 
hypothyroidism may have normal birth weight 
and height (although the head may be larger 
than expected and the posterior fontanelle may 
be open). Some may have drowsiness, 
decreased muscle tone, a hoarse-sounding cry, 
feeding difficulties, constipation, an enlarged 
tongue, umbilical hernia, dry skin, decreased 
body temperature and jaundice [4,5]. 
 
Levothyroxine sodium (LVX) is used for the 
treatment or prevention of various types of 
deficiency such as hypothyroidism, cretinism, 
non-toxic goitre, myxoedema and coma in 
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newborn, infants and children [6]. LVX is also 
effective in the suppression of pituitary thyroid 
stimulating harmone (TSH) secretion in the 
treatment or prevention of various types of 
euthyroid goiters. LVX tablets are available in the 
market for the treatment of hypothyroidism for 
pediatrics. [7]. One of the greatest challenges in 
pediatric pharmacology has been optimization of 
oral drug delivery. In a recent study, 54 % of 
children between the ages of 6 and 11 years told 
study investigators that they were unable to 
easily swallow a tablet [8,9].  
 
Oral fast-disintegrating film containing active 
drug molecule is a delivery technology for the 
oral delivery of drugs as an alternative to 
conventional dosage forms such as tablets, 
capsules, syrups and other formulations, for 
pediatric and geriatric use. Oral fast 
disintegrating films are easy to administer and 
provide better patient compliance in the elderly, 
pediatric, mentally retarded, nauseated and 
uncooperative patients [10]. Thus, the aim of the 
present study was to develop oral fast-
disintegrating films of LVX for the management 
of hypothyroidism in pediatrics for improved 






Levothyroxine (LVX) was purchased from Baoji 
Guokang Bio-Technology Co., Ltd. (Baoji, 
Shaanxi, China), hydroxypropyl methylcellulose 
(HPMC) and croscarmellose sodium (CCS) was 
purchased from Sigma Aldrich, USA. Propylene 
glycol and sorbitol were purchased from 
Shanghai Chemical Co. (Shanghai, China). 
 
Preparation of fast disintegrating films 
 
Fast-disintegrating film of LVX was prepared by 
solvent-casting evaporation method [11]. The 
composition of the formulation is presented in 
Table 2. The required quantity of polymer 
(HPMC) and plasticizer (propylene glycol) was 
dissolved in double distilled water. This polymeric 
dispersion was stirred for 1 h using magnetic 
stirrer at 500 rpm and kept aside to remove all 
the air bubbles entrapped. In another beaker the 
aqueous solution was prepared by dissolving 
specified quantities of LVX, CCS and sorbitol in 
specific proportion in the mixture of distilled water 
and alcohol. Polymeric dispersion was added to 
solution containing LVX and stirred for 1 h. After 
removal of air bubbles, the polymeric solution 
containing drug was casted into glass petridish of 
specified dimension (30 cm2) and dried in the 
vacuum oven at 28 oC for 24 h. The film was 
carefully removed from the Petri dish, observed 
for any imperfections and cut into circular pieces 
(5 cm2). 
 
Table 1: Variable and three levels 
 




Independent   
A= HPMC Conc. 30 40 
B= CCS Conc. 2 4 
C= PG Conc. 10 15 
Dependent    
Y1= DT   
Y2=%DR   
 
23 factorial design for formulation of films  
 
Statistical analysis of the experimental work was 
carried out using Design Expert 6.0.8 portable 
software. A 3-factor, 2-level full factorial design 
was used to derive a second order polynomial 
equation.  Concentration of HPMC (A), CCS (B) 
and Propylene glycol (C) were selected as a 
independent variables while disintegration time 
(Y1) and in vitro drug release (Y2) were selected 
as a dependent variables. Variables and three 
levels are presented in Table 1. 
 
Table 2: Formulation of LVX fast disintegrating films 
using 23 Factorial Design 
 
 
Physical evaluation of films 
 
Smoothness, color, clarity, transparency of oral 
films was examined visually. Thickness of film 
formulations were evaluated by using micrometer 
screw gauze. The thickness of 5 film pieces was 
taken and the mean was taken. The surface pH 
of the film was determined by placing the film in 
petridish, slightly wet with the help of distilled 
water. The pH was noted by bringing the surface 
of the film in contact with pH meter electrode for 
one minute. Folding endurance test was 
performed by repeatedly folding the film at the 
same place until it broke. The number of times 
the film could be folded at the same place 
without breaking or cracking gave the value of 
folding endurance [12]. 
 
Batch Factor                                    Response 
A B C Y1 Y2 
F1 +1 +1 +1 15 97.56 
F2 +1 -1 +1 52 85.29 
F3 +1 -1 -1 45 80.78 
F4 -1 +1 +1 25 88.32 
F5 -1 +1 -1 18 92.3 
F6 +1 +1 -1 20 90.11 
F7 -1 -1 +1 55 82.35 
F8 -1 -1 -1 60 78.25 
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Content uniformity test  
 
Each film was soaked and dissolved in 20 ml of 
dichloromethane and resulting solution was 
filtered to remove undissolved residue. Aliquots 
were prepared and measured for drug content at 
297 nm using UV spectrophotometer (Schimadzu 
1700) [13].  
 
In vitro disintegration time (DT) test 
 
In vitro DT of each film was determined in pH 6.8 
phosphate buffer. Approximately 25 ml of 6.8 
phosphate buffer was placed in a Petri dish. The 
film (1 cm2) to be evaluated for DT was placed in 
this petri plate and time taken by each film to 
complete disintegrate was noted and considered 
as DT [13]. 
 
Ex vivo permeation studies  
 
Ex-vivo permeation studies were carried out 
through porcine oral mucosa using specially 
designed glass diffusion cell. All animal 
procedures were conducted in accordance with 
all appropriate regulatory standards according to 
the protocol approved by the Institutional Animal 
Care and Use Committee of the Xinxiang 
Medical University (approval no. 
Xing/col/FA2145). The animal studies were 
performed as per the international CPCSEA 
guidelines. Porcine oral mucosa was soaked 
previously for 24 h in pH 6.8 phosphate buffer 
[10,13]. This oral mucosa was stretched around 
one end of the diffusion cell. The working surface 
area of the membrane was 3.5 cm2. Donor 
compartment (tube) was adjusted into a glass 
beaker containing pH 6.8 phosphate buffer 
(receptor compartment) in such a way that, the 
oral mucosa just touched the receptor medium. 1 
cm2 weighed buccal film was placed on the oral 
mucosa. The receptor medium was maintained 
at 37 ± 0.5 °C and stirred at 50 rpm. 5 ml aliquots 
of samples were withdrawn from the receptor 
medium at predetermined time intervals and 
replaced with equal volume of fresh buffer to 
maintain the sink condition. Samples were 
analysed with UV-Spectrophotometer at 297 nm 




Statistical analysis of the experimental work was 
carried out using Design Expert 6.0.8 portable 
software. A 3-factor, 2-level full factorial design 
was used to derive a second order polynomial 
equation.  The contour plots were constructed to 





Physical characteristics of films 
 
LVX fast disintegrating films were prepared by 
solvent casting evaporation technique were 
transparent, smooth, soft, and colorless in 
nature.  Drug content uniformity of was in the 
range of 97.59 to 99.58 % while the while 
thickness of the film was in the range of 0.17 to 
0.30 mm. Folding endurance of the film ranged 
from 160 to 200, and pH of the film was 6.63 to 
7.13. All the physical parameters are 




Patient compliance, convenience of 
administration of the dosage form and safety are 
the major factors considered during the 
development of the dosage form for pediatric 
patients suffered from disorders of the endocrine 
system like hypothyroidism, goiter etc [14]. 
Commercially available dosage forms for 
pediatrics like tablets, capsules, oral liquid 
medications have lot of disadvantages e.g. 
patient compliance, inability to swallow a dosage 
form [14]. So in order to avoid such drawbacks 
fast disintegrating films offer great potential for 
rapid and convenient drug delivery technology for 
the pediatric patients. 
 
Table 3: Physical characteristics of films 
 






pH Film nature 
F1 98.90 200 0.17 6.70 Transparent 
F2 99.20 175 0.20 7.13 Smooth 
F3 98.50 185 0.22 6.90 Smooth 
F4 99.56 145 0.25 6.87 Soft 
F5 97.59 220 0.24 6.73 Soft 
F6 99.58 160 0.30 6.90 Smooth 
F7 98.54 180 0.23 6.63 Transparent 
F8 97.80 165 0.21 6.65 Transparent 
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Such fast disintegrating films are more 
acceptable to patients with hypothyroidism, 
goiter, dysphagia in pediatric patients. These 
films are mainly consisting of hydrophlic polymer, 
superdisintegrants, plasticizers, sweeteners etc 
which gets dissolved in mouth within seconds. In 
this experiment the minimum DT of 15 seconds 
was successfully achieved by using CCS as a 
superdisintegrant. These films are to be placed 
on the tongue for oral absorption, under the 
tongue for sublingual absorption. Such route 
bypass gut absorption and delivery into the 
hepatic portal system, thus avoiding the first pass 
metabolism and increasing the 
bioavailability[20].The first FDA approved oral 
disintegrating film is ondendetron (Zuplenz®) 
which was approved on 2010. Also several films 
of rizatriptan, rotavirus vaccine and levocetrizine 
have been under development. These 
developments and FDA approval clearly 
indicates the importance of these films in 
pediatrics and other type of patients who have 
problem of swallowing and patient 
compliance[15]. 
 
In vitro disintegration time (DT) was determined 
in 6.8 pH phosphate buffer. Generally the pH of 
saliva ranges from pH 6.2 – 7.4. DT was 15 to 60 
s as shown in Table 4. 
 
From the results presented in Table 4 it clearly 
indicated that the formulated films had fast 
disintegrating nature at saliva pH. The 
polynomial equation obtained for DT (Y1) is 
given in Eq 1.  
 
Y1 = + 36.25-3.25A-16.75B+0.50C+0.000BC..(1) 
 
where Y1 is the DT, A is HPMC concentration, B 
is CCS concentration and C is propylene glycol 
concentration.  
 
Table 4: DT and % DR at t = 1 h 
 
Batch  DT (s) DR (%) 
F1 15 97.56 
F2 52 85.29 
F3 45 80.78 
F4 25 88.32 
F5 18 92.30 
F6 20 90.11 
F7 55 82.35 
F8 60 78.25 
 
The model F- value 0.0160 indicates the model is 
significant (p < 0.05). A positive value in above 
equation represents the synergistic effect of the 
independent variable and a negative value 
represents the antagonistic effect [16]. The 
suggested model for the Y1 was found to be 2FI 
as shown in Table 5. 
 
The value of correlation coefficient (R2) for the 
response Y1 was 0.9650 which indicates good fit 
for the 2 FI model. The p-value for the Y1 model 
was 0.0160 which clearly indicates the model is 
statistically significant, viz, the three independent 
variables selected for all the factors: A (p = 
0.0045), B (p = 0.0030), C (p = 0.0035). The data 
are shown in Table 6. 
 
The polymer used for the preparation of film had 
good film forming property with non-toxic, non-
irritant, good wetting properties [10]. This 
polymer played important role in imparting 
necessary mechanical properties to the film. It 
also influenced the DT of the film. As can be 
seen from contour plot Figure 1(A) as the 
concentration of HPMC increases from 30 to 40 
% the DT of the patches was found to be 
increased. Increase in the concentration of 




Table 5:  Summary of results of regression analysis for responses Y1 and Y2 
 
Model R2 Adjusted  R2 Predicted R2 Std. Dev Press Remarks 
Response Y1       
Linear 0.8260 0.8035 0.6514 7.36 510.20 ……… 
2FI 0.9650 0.9184 0.7512 5.31 600.89 suggested 
Quadratic 0.9265 0.9072 0.7825 0.45 550.30  
Cubic 0.9120 0.8966 0.5912 0.49 462.20 ……… 
Response Y2       
Linear 0.6599 0.6090 0.3563 3.75 120.73 ……… 
2FI 0.9353 0.8491 0.5402 2.50 133.65 suggested 
Quadratic 0.9020 0.8871 0.8598 4.90 112.30 ……… 
Cubic 0.9114 0.9025 0.8790 6.50 125.36 ……… 
Regression equations of the fitted models 
Y1 = +36.25-3.25A-16.75B+0.50C+0.000BC 
Y2 = +86.87+1.57A+5.20B+1.51C+1.48AC 
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Table 6: ANOVA of models for Y1 and Y2 
 
Source DF Sum of squares Mean square F-value P-value 
Model for Y1 4 2331 582.75 20.69 0.0160 
A 1 84.50 84.50 3.00 0.0045 
B 1 2244.50 2244.50 79.69 0.0030 
C 1 2.00 2.00 0.071 0.0035 
BC 1 0.000 0.000 0.000 1.000 
Model for Y2 4 271.89 67.97 10.85 0.0395 
A 1 19.59 19.59 3.13 0.0351 
B 1 216.53 216.53 34.56 0.0098 
C 1 18.24 18.24 2.91 0.02865 




Figure 1: (A):Effect of HPMC on DT of film; (B): Effect of CCS on DT of film; (C): Effect of PG on DT; (D): Effect 
of HPMC on DR from the films 
 
From above polynomial equation it was also 
clear that the HPMC concentration (A) has 
negative effect on DT as coefficient of A is -3.25. 
The possible reason for such increase in DT was 
the formation of more dense polymeric 
dispersion that led to resist in disintegration of 
the formed film [17]. 
 
CCS was used as a superdisintegrant in films to 
minimize the DT of the oral films containing the 
LVX. From the contour plot in Figure 1(B), it is 
clear that as the concentration of CCS increased 
the DT get decreased. This effect was 
statistically significant B (p = 0.0030). The 
minimum DT was 15 s at concentration of 4 % 
CCS. CCS has been already utilized in tablets, 
capsules and films to adjust the DT of the 
formulation. CCS is having great swelling and 
minimum gelling capacity at low concentration 
ranging from 2.0 to 6.0 %. Above 8.0 %, it shows 
higher gelling property with increased viscosity 
that result into increase in DT. So in this study 
the concentration was maintained at 2.0 and 4.0 
%. CCS is a cross linked polymer of 
carboxymethyl cellulose sodium. Cross linking 
makes it insoluble, hydrophilic, highly absorbent 
material, resulting in excellent swelling properties 
and its unique fibrous nature gives it excellent 
water wicking capabilities [18]. 
 
Propylene glycol was used as a plasticizer to 
impart strength to the oral film. Also it was 
responsible for increasing the flexibility, 
preventing brittleness or breakage of the film. In 
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this film development the PG was used in two 
levels (10 and 15 %). The PG had also negative 
effect on the DT. As the concentration of PG was 
increased from low level to high level, the DT 
was found to be increased as in Figure 1(C). But 
increasing concentration of PG had improved the 
strength of the film making it more acceptable for 
oral use. Plasticizer act by inserting themselves 
between the polymer strands and break the 
polymer-polymer interactions and increases the 
molecular mobility of the polymer strands [19]. 
Greater physical strength at higher levels of PG 
led to higher impart resistance to break the film, 
resulting in increased DT. 
 
Drug release study was carried out at saliva pH 
(6.8) to simulate the condition. The drug release 
was found to be in the range of 78.25 to 97.56 % 
as shown in Table 4. The polynomial equation for 
DR as given in Eq 2. 
 
Y2 = +86.87+1.57A+5.20B+1.51C+1.48AC…. (2) 
 
The model F-value 0.0395 indicates the model is 
significant (p < 0.05). The suggested model for 
the Y2 was found to be 2FI as shown in Table 5. 
The value of correlation coefficient (R2) for the 
response Y2 was 0.9353 which indicates the 
good fit for the 2 FI model. The p-value for the Y2 
model was found to be 0.0395 which clearly 
indivates the model is statistically significant. 
Also among the three independent variables 
selected all factors A (p = 0.0351), B (p=0.0098), 
C (p = 0.02865). Data shown in Table 6. 
Diagnostics case statistics for various response 
variables are shown in Table 7.  Comparative DR 
profile is given in Figure 2. 
 
Figure 2: Comparative drug release profile of the films 
in 6.8 pH phosphate buffer 
 
From the contor plot Figure 1 (D), drug release 
decreased as the amount of polymer increased 
from 30 to 40 %. As HPMC form a matrix at 
physiological pH, it retarded the release of the 
drug from the film. Hence at higher concentration 
of the polymer, drug release was lower 
compared to the lower level of polymer 
concentration. HPMC is the hydrophilic polymer 
which absorbs the water and forms the gel this 
gel is responsible for the retardation of the drug 
from the film system. Hydrophilic polymers create 
the pore and the channels on the film surface 
that led to release of the drug from the film 
[20].The effect of HPMC on DR was found to be 
statistically significant. The CCS has also a 
significant effect on the DR. The effect is shown 
in Figure 3(A). As discussed above it also has 




 Figure 3: (A) = Effect of CCS on DR from the films; (B) = Effect of PG on DR from the films 
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Due to swelling of the film it favored the release 
from the film. Due to disintegrant property of 
CCS, it helped to break the film at saliva pH and 
that resulted in to the fast release of the LVX 
from the film. CCS has positive effect on DR as 
that seen in DT. DR from the film system was 
also affected by concentration of plasticizer and it 
had a direct relationship when the concentration 
of the plasticizer was increased as shown in 
Figure 3 (B). A positive coefficient in above 
equation clearly indicates the favourable effect 
on the DR. LVX oral fast disintegrating films has 
also been developed with the intention to 
improve the patient compliance in pediatrics who 
are suffering from the endocrine disorder 
hypothyroidism and goiter. These films had great 
pharmaceutical acceptance in terms of the 
physical appearance, strength, pH, folding 
endurance, uniform drug content within films. All 
selected independent variables had great 
influence on DT and DR. HPMC being hydrophlic 
polymer played great role in the development of 
the LVX films. HPMC imparted good strength to 
the films and controlled the release from the 
films. Also CCS was the key excipient in the films 
to maintain the DT at saliva pH. Its mechanism is 
already discussed in result part. The effect of 
CCS was found to be statistically significant in 
case of both independent factors. The same 
effect was observed in case of the PG. Definitely 
these oral fast disintegrating films could be novel 
technology for the pediatric patients for the 




Oral fast disintegrating LVX films can be 
successfully prepared using the HPMC, CCS and 
PG. Such an oral fast disintegrating film is a 
potentially suitable delivery system for pediatric 
patients who have swallowing problem of other 
solid dosage forms, and can thus be used in the 
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